Automatic closed-loop administration of sodium nitroprusside for the regulation of blood pressure in patients experiencing acute hypertension has been the subject of intense research over the last three decades. Yet, to date, manual administration of vasoactive drugs by a human operator remains the standard of care in the clinical setting. This manuscript describes a novel control approach for this application based on Robust Multiple-Model Adaptive Control (RMMAC). The RMMAC architecture features robust controllers designed with µ synthesis and Kalman filtering for system estimation. The new system was coupled with a mathematical model of a patient's response to drug infusion and tested in computational simulations. The results indicate that the RMMAC approach has the potential to deliver robust performance even in challenging operating conditions, with mean arterial pressure remaining within the specified target range over 99% of the time.
Introduction
Patients undergoing major surgery (especially cardiovascular surgery) may experience episodes of acute blood pressure elevation during the intra-and postoperative periods. Such episodes may last between a few minutes and several hours and involve a hightened risk of complications for the patient, such as cardiovascular or cerebrovascular accidents. Careful management of acute hypertension is therefore required and is generally achieved by infusion of suitable vasoactive drugs by clinical operators [1] .
Due to considerable variability in drug sensitivity among patients and even for the same patient over time, the correct infusion rate cannot be determined a priori and dose titration is required. This is a tedious and time consuming task for clinical personnel, and manual titration can be imprecise. In this context, the development of a closed-loop system capable of automatically adjusting the drug infusion rate to maintain a patient's mean arterial pressure (MAP) within a prescribed range would represent a valuable contribution to medical technology [2] . The benefits of such a system would be an improvement in patient outcomes by reducing the likelihood of complications, removing the risk of human errors, and the possibility of allocating human resources to more critical tasks.
This work focuses on the challenge of automatic closed-loop control of sodium nitroprusside (SNP) infusion. SNP is a powerful and fast-acting vasodilator drug which lowers blood pressure by causing a drop in both arterial and venous resistance. It should be acknowledged that SNP is no longer routinely used for the treatment of hypertension and other, more recently discovered drugs are generally preferred when available [1] . However, SNP remains a useful case study since a mathematical model of the dose-effect relationship exists and has been clinically validated [3] . A variety of approaches to blood pressure control by closed-loop SNP infusion have been proposed over the past three decades (see [4] for a review). While the potential benefits of such a technology remain undisputed, however, it is notable that only one of these designs ever reached commercial production in the early 1990s, and that the resulting device enjoyed such little success that it was discontinued soon after being marketed [5] , despite seemingly promising results in premarket clinical trials [6] .
In earlier work [7] , we have analysed an adaptive control strategy proposed in the mid-1980s [8] and advocated caution against instances of inadequate MAP control which may arise as a result of particular operating conditions generated by a combination of disturbances and variations of patient parameters over time. We have argued that, although unlikely, the occurrence of such operating conditions could not be excluded a priori, and suggested that this may impact negatively on the perceived safety of automatic closed-loop drug delivery systems, discouraging their uptake in the clinical setting. Such concerns may be even more pertinent when the technology proposes to assist not only with relatively steady patients recovering in the intensive care unit, but also with more challenging cases such as may be encountered in intraoperative settings.
This paper introduces a novel control approach for this closed-loop drug delivery problem based on a Robust Multiple-Model Adaptive Control (RMMAC) architecture [9] . RMMAC adopts modern control engineering techniques such as µ synthesis for controller design and Kalman filtering for system estimation in order to ensure Figure 1 . Block diagram of the patient model. T is the pure delay parameter; τ 1 = 50s, τ 2 = 30s, τ 3 = 10s are the time constants of the first-order LTI subsystems; α is the recirculation parameter; K is patient sensitivity.
adequate system performance irrespectively of model uncertainties, disturbances and parameter variations. The ability of the RMMAC system to deliver robust performance is shown through computer simulation results.
2 Problem Description
The Patient Model
The model considered to describe the patient response to SNP infusion is a linear system with delay found in [8] . It is a modified version of the model originally identified by Slate and coworkers [3] . A block diagram is provided in Figure 1 . The transfer function of the system is given by
and the output is given by the affine relationship
where U (s) is the rate of drug infusion, p drop is the drop in pressure caused by the drug effect, the measurable output y meas is MAP, p 0 is the patient's "baseline" blood pressure, i.e., the value of MAP which the patient would display in the absence of pharmacological intervention, and w is random measurement noise. The core of the system consists of three interconnected low-pass linear time-invariant systems representing the pulmonary circulation, the systemic circulation, and the drug effect site. The patient sensitivity parameter K ∈ [0.25 9.5]mmHg/(ml/hr) determines the steady-state gain of the system; the recirculation parameter α ∈ [0.25 0.75] reflects the metabolism of SNP, i.e. what percentage of the drug is retained each time it is circulated through the body; a delay effect at the input is modelled by the delay parameter T ≤ 50s. The system of Equation (1) is open-loop stable: this should not come as a surprise since in current clinical practice MAP control is routinely achieved via open-loop drug administration. In the interest of utilising an as general description for intrapatient varibility as possible, all uncertain parameters are assumed to be potentially time varying across the full range of parametric variability. The rate of variation of the sensitivity parameter K, which has the largest uncertainty range and therefore represents the biggest challenge for control design, is limited to a four-fold change
. . . [10] . Baseline MAP p 0 is also deemed time varying and, for the purpose of simulations, is a signal generated through a combination of random (gaussian, with zero mean and variance 10mmHg), step and sinusoidal components filtered by a low-pass filter. To the author's knowledge, this is the most unconstrained modelbased formulation ever adopted for this problem.
Performance Specifications
There is substantial agreement in the literature that closedloop control of MAP should achieve:
• a settling time of 10min or less;
• a maximum overshoot of 10mmHg during transients;
• during steady state operation, MAP should be contained within ±5mmHg of the desired set-point value;
• under no circumstances should the system display resonant (persistent oscillatory) or unstable behaviour or cause MAP to drop below a pre-determined threshold level (danger threshold).
Since the drug is administered intravenously, an infusion pump is part of the control loop. The design must therefore consider actuator slew rates by imposing suitable bandwidth constraints. Also, metabolic toxicity resulting from SNP decomposition into cyanide compounds imposes an upper limit for drug infusion rate at 3ml·kg
3 Control architecture Figure 2 shows a block diagram of the RMMAC architecture. The underlying idea of a multiple-model adaptive control system is that the behaviour of the plant (in this case, the patient's MAP response to SNP infusion) can be matched with that of one of a series of models included in a model bank. A suitable controller for the best matching model is selected from a controller bank and is placed in the feedback loop, where it is expected to yield satisfactory performance. The two key aspects of the method are therefore robust controller design and reliable plant-model matching.
Controller design
In RMMAC, controller design is carried out using µ synthesis. A detailed description of the µ synthesis technique applied to this problem can be found in [12] and only a qualified summary will be provided here. The µ synthesis approach allows the control designer to compute a linear controller capable of meeting a specified minimum level of performance in the presence of a given amount of modelling uncertainty and in the face of exogenous disturbances, if one such controller exists. The performance requirements are incorporated into the problem formulation as upper bounds for signals u and (y meas − r) in the frequency domain. Similarly, worst-case upper bounds for signals p 0 and w are used to incorporate a description of expected exogenous disturbances. By utilising µ synthesis in an iterative algorithm, we were able to demonstrate that the performance requirements of Section 2.2 could not be met with a single controller for all possible operating conditions, thus supporting the need for multiple controllers. Performance could indeed be achieved by designing controllers over subsets of the parametric uncerainty space. In our design, all controllers could cater for the full uncertainty range for the delay term T and recirculation fraction α, and cover a subset of the uncertain for the sensitivity parameter K. Table 1 summarises the results of the controller design process.
It should be emphasised that controllers designed with µ synthesis can guarantee robust performance. Provided that the actual patient behaviour falls in the design parameter subset for one of the controllers, and that the disturbances do not exceed the design bounds, the closed-loop system with that controller in the loop will meet the prescribed level of performance irrespective of parameter variations (within the design subset) and the presence of disturbances. This guarantee is relevant due to the importance of safety in such a critical application.
Patient-Model Matching
The actual behaviour of the system is matched to one of 5 candidate models (a one-to-one correnspondence between the candidate models and the parametric subsets used for controller design). This is achieved by a bank of Kalman filters and a posterior probability estimator (Figure 2 ).
Kalman Filters
Each Kalman filter uses information from the input signal u(t) and measured output y meas (t) to generate a one-step- ahead estimate of the statex i (t + 1) and corresponding outputŷ i (t + 1) on the basis of the ith candidate model (i ∈ {1, 2, ..., N }) through a predict-update cycle as shown below: predict cycle:
update cycle:
where the notationâ(t + 1|t) indicates the estimate of a at time t + 1 using information available up until time t; r i is the residual signal given by the difference between the estimate and the actual observed output; A i , B i and C i are the matrices describing a state-space realisation of the ith model, refer to Table 1 and Equation (1); H is the Kalman filter innovation gain. In order to reproduce the original RMMAC approach of [9] , a steady-state formulation for the Kalman filter was used. This means that H was determined a priori on the basis of knowledge of the variance of the gaussian components of the disturbance signals (baseline pressure and measurement noise -p 0 and w, respectively, in Figure 2 ) and was the same for all filters in the bank. Finally, it should be pointed out that the nominal parameter values used to generate the 5 candidate models fall inside the respective subsets listed in Table 1 but are not necessarily centered (e.g., the nominal value of K used for model 5 is 9.0 although the centered value for the uncertainty subset 6.75 ≤ K ≤ 9.5 would be 8.125). The reason for this is a result from probability theory by which only the choice of particular nominal parameter values ensures convergence of the posterior probabilities described in Section 3.2.2. A more detailed explanation is beyond the scope of this manuscript and interested readers can refer to [13] . A drawback of the approach described thus far is that Kalman filtering requires that the system be lineargaussian. From the description of Section 2.1 it is clear that this assumption is violated here due to the presence of non-gaussian disturbance p 0 , and an unknown yet potentially large delay term. For now, we assume that nongaussian signal components can be taken to be either zeromean signals of lower magnitude than the gaussian components (which can, therefore, be dealt with by increasing the anticipated value for noise variance for the purpose of determining the innovation gain H) or non-zero-mean signals slower than the system's dynamics (which can, therefore, be dealt with through the Kalman filter's inherent adaptive capability). Simulations provided in [13] show that RMMAC can deal with some degree of non-gaussianity under these conditions. Clearly, these assumptions could have implications in terms of the method's safe applicability in the clinical setting and will be discussed further in Section 6. The issue of delay, however, is a more challenging one, as Kalman filters do not provide good estimates for systems with variable time delays. A workaround for this problem was developed by adding redundancy to the estimation bank, as shown in Figure 3 . The 5 Kalman filters discussed earlier were generated on the basis of the linear part of the system alone, neglecting the delay. The bank was then duplicated five times, with different amounts of delay (10s, 20s, 30s, 40s and 50s) being applied to the drug infusion signal u entering each of the duplicate banks. Plant-model matching was therefore carried out on 25 candidates: 5 candidate models, each with 5 delay cases.
Posterior Probability Estimator
The 25 residual signals are then used in the following recursive posterior probability estimation:
where N = 25 is the number of candidate cases; r j (t); j = 1, . . . , N is the difference (residual) between the measured output y and the j-th output estimateŷ j ; S j is the steady state residual covariance matrix of r j (t);
is a constant scaling factor, and P j (t)
is the probability that model j is the model which best represents the patient behaviour at time t. This formulation is the same as adopted in [9] . P i (0) = 0.04 for all i. On the basis of P i (i = 1, . . . , N ), a switching signal σ(t) for controller selection is generated as the sum of the probabilities that model k (k = 1, . . . , 5) is the best match in any of the considered delay cases N T = 5:
Finally, the control signal u(t) is given by
where u k (t) is the control signal generated by controller C k (k = 1, . . . , 5) in the controller bank ( Figure 2 ). Drug infusion is therefore computed as a sum of the control action from all candidate controllers, weighted by the probability of a match between the model parameter subset associated with each controller and the actual behaviour of the patient.
Numerical Simulations
The RMMAC control architecture for closed-loop control of MAP by SNP infusion described in the previous section has been implemented in Matlab and Simulink and tested in a simulation study. The discrete time step used in the Kalman filter and posterior probability computations is 2 seconds (roughly equivalent to sampling MAP every 1 to 2 heart beats). We present here four simulated cases. In all simulations, the MAP of a hypertensive patient is to be controlled over a period of several hours according to a step-wise reference signal. The specific characteristics of the four simulated patients are as follows:
1. a patient with steady parameters and low-magnitude (variance 4mmHg) random fluctuations of baseline pressure;
2. a patient with rapidly changing sensitivity to SNP but a steady time delay and full-magnitude (variance 10mmHg) random fluctuations of baseline pressure;
3. a patient with steady sensitivity to SNP but varying time delay and full-magnitude random fluctuations of baseline pressure;
4. a patient with varying sensitivity and time delay, as well as non-zero-mean, non-random changes to baseline pressure.
The four cases represent patients in which the conditions for MAP stabilisation range from relatively straightforward, as may occur in an uncomplicated recovering patient, to extremely challenging, as may be encountered in an intraoperative setting. For each case, data on p 0 , output MAP, parameter values for K and T , drug infusion rate u (Equation (7)) and model probabilities P i (Equation (5)) were extrapolated from the simulation. Figure 4 shows the results of the first simulation. The RM-MAC system is capable of maintaining MAP within the allowed error range. Identification of the correct model, after the commencement of closed-loop control (the reference setpoint is lowered to 100mmHg at approximately t = 17min) is fast and takes approximately 5 minutes.
Results
The results of the second simulation, reported in Figure 5, show another instance of good performance of RM-MAC. It should be noted that the allowed error range for this simulation and the ones that follow is increased to ±10mmHg as we deem the system to be displaying transient behaviour throughout the simulation due to the presence of time-varying parameters. The closed-loop system is successful at tracking the required MAP setpoint, with the exception of two MAP spikes which violate (albeit marginally) the allowed error range. Upon closer inspection, it appears that the spikes occur when the probability result shifts between different models, leading to temporary discontinuity in the control action, as can be observed in the infusion rate graph at approximately 2.7 hours.
The system exhibits good performance also in the third simulation, as shown in Figure 6 , where controlled MAP remains within the prescribed range throughout the simulation. This case is a good example to observe how the presence of time-varying delay can make the match between the process behaviour and a candidate model less accurate. In this simulation, the patient is initially matched with model 4, although the sensitivity parame- Figure 6 . Results of simulation for case 3. Acceptable error range for controlled MAP is ±10mmHg. The presence of time-varying delay renders the posterior probability estimation less accurate, but performance is still adequate thanks to the inherent conservativeness of µ synthesised controllers.
ter does not remain for long inside the range for model 4 (3.48 ≤ K ≤ 6.72). Also, by inspecting how closely the computed model probabilities follow the actual value of K, it is clear that the results were more accurate in the second simulation. Despite so, the performance of the system is acceptable. This is largely a result of the conservative nature of µ synthesis as a controller design technique: the computed controllers are likely to be capable of robust performance for an uncertainty range broader than the design subset.
Finally, the fourth simulation shows that the system is capable of delivering satisfactory performance even in the presence of non-zero-mean disturbances -in this case, a DC change in p 0 representing worsening hypertension.
In no cases did the system display transient instability, oscillatory behaviour, or MAP drops below the safety threshold of 60mmHg. Over the 16 hours of simulated control presented here, MAP remained in the prescribed range 99.3% of the time. The drug infusion rate was at all times well below the toxicity threshold for SNP infusion of approximately 110 ml/hr calculated for a generic 70kg patient. Toxicity was not a concern despite the presence of low sensitivity values in the simulated patients. The maximum rate of change of SNP infusion was only approximately 0.5(ml/hr)/s, which should be within the capability of a motorised infusion pump.
Discussion, Future Work and Conclusion
We have presented a novel architecture for closed-loop control of MAP by automatic administration of SNP. The approach, based on the RMMAC framework of [9] , makes use of modern control engineering tools to deliver robust performance in the face of time-varying parameters, modelling uncertainty and generic disturbances.
RMMAC has the potential of incorporating knowledge about uncertainty in the drug dose-effect model at the design stage. This characteristic makes it particularly suited to applications in the medical field, where it is common for regulatory authorities to require a priori assurances on the safety of a proposed technology. It should be emphasised once again that SNP has been chosen as a case study due to the existence of a validated pharmacological model and the availability of previous closed-loop MAP control results in the literature which will be the compared with the performance reported here as part of future work. However, RMMAC could be applied in other contexts where a model is available. The approach can be used to control both linear (as in the case presented here) and non-linear systems, as the use of multiple models allows the latter to be treated as an interpolation of locally valid linear models.
The results of the simulation studies are positive and encouraging. We argue that by extending the range of operating conditions in which automatic closed-loop drug delivery can perform effectively and safely -and RMMAC may be a way to do so -it may be possible to overcome clinicians' reservations in terms of real and perceived risks associated with removing human operators from the loop. There are, however, further clinical and engineering aspects which need to be considered before the RMMAC approach can be applied in a real clinical setting.
The key engineering issue concerns the use of Kalman filtering for patient-model matching. As we have already acknowledged, Kalman filtering is not the estimation tool of choice in the presence of dead times and non-gaussian signals. Indeed, convergence of (5) to the correct model can only be mathematically guaranteed in an ideal environment with gaussian-only input signals, which is clearly not the case here. Due to the violation of this assumption, the RMMAC system presented cannot be deemed robust in a strict control engineering sense. Satisfactory robust performance can only be evaluated -and has been shown -heuristically through the results of simulations. Future work will investigate alternatives to Kalman filtering to ensure reliable patient-model matching in a non-Gaussian and possibly non-linear context.
From a clinical point of view, a key concern is whether regulation of MAP alone by infusion of a vasodepressor drug is a sufficient condition to ensure patient safety. Indeed, the task of managing perioperative hypertension has been defined as something of an art [1] . It is possible that a system administering a single vasoactive drug may be too limited to be of practical use, or that joint control of multiple cardiovascular variables may be preferable (as suggested recently in [14] ). Further consultation with clinical specialists is therefore required. In any case, provided that pharmacokinetic and pharmacodynamic models for drug action and drug interactions are available, the same approach presented here could be extended to handle a multiple-input multiple-output case.
